UbcH5c-IN-6d;UbcH5c-IN-1;Naphtho[1,2-b]furan-2(3H)-one, 8-[(2-bromophenyl)methoxy]-3a,4,5,9b-tetrahydro-6,9-dimethyl-3-methylene-, (3aS,9bR)-;UbcH5c IN 1,UbcH5cIN1,UbcH-5c-IN-1
UbcH5c-IN-1 is a potent and selective small-molecule inhibitor of the ubiquitin-conjugating enzyme UbcH5c, acting as a lead compound for the development of novel therapeutics for rheumatoid arthritis; it significantly reduces arthritis index scores and hind paw swelling in a Freund’s complete adjuvant (CFA)-induced adjuvant arthritis (AA) rat model upon oral administration (5 and 20 mg/kg daily from day 10 to 20 post-immunization).